Allergan v Sandoz

News & Analysis as of

Allergan, Inc. v. Sandoz Inc.

Case Name: Allergan, Inc. v. Sandoz Inc., Case No. 11-cv-441, Dkt. No. 136 (E.D. Tex. Jan. 13, 2014) (Schneider, J.) - Drug Product and Patent(s)-in-Suit: Lumigan® (bimatoprost); U.S. Patents Nos. 7,851,504 (“the ’504...more

Recent Ruling Clarifies Patent Litigation Timing Under Biosimilars Act

The first court decision interpreting the Biosimilars Act has arrived, with a federal district court in California finding that a biosimilar application must be filed with the FDA before patent litigation can be initiated....more

Federal Circuit Review - Volume 3 | Issue 5 - May 2013

In This Issue: • Patent Office Must Prove Prior Art Reference Is Enabling • Complaint Was Adequate Despite Non-Infringing Possibilities • FDA Approval Not Relevant to Obviousness Analysis - Excerpt from...more

Patent Watch: Allergan, Inc. v. Sandoz Inc.

On May 1, 2013, in Allergan, Inc. v. Sandoz Inc., the U.S. Court of Appeals for the Federal Circuit (Dyk, Prost,* O'Malley) affirmed-in-part and reversed-in-part the district court's judgment that U.S. Patents No. 7,642,258,...more

4 Results
|
View per page
Page: of 1